2021 ISAKOS Biennial Congress Paper
Prospective Study Comparing Leukocyte-Poor Platelet Rich Plasma Combined With Hyaluronic Acid And Autologous Microfragmented Adipose Tissue In Patients With Early Knee Osteoarthritis.
Ignacio Dallo, MD, Sevilla SPAIN
Macarena Morales, MD, milano, lombardia ITALY
Alberto Gobbi, MD, FRACS, Milan ITALY
O.A.S.I. Bioresearch Foundation Gobbi NPO, Milan, MI, ITALY
FDA Status Not Applicable
Summary
The purpose of this study is to evaluate the clinical efficacy of repeated doses of Leucocyte-poor Platelet-rich Plasma combined with Hyaluronic Acid and single dose of Adipose Derived Mesenchymal Stem Cells injections. It was hypothesised that Adipose Derived Mesenchymal Stem Cells could be superior to Leucocyte-poor Platelet-rich Plasma + Hyaluronic Acid for the treatment of early knee Osteoarth
Abstract
Purpose
The purpose of this study is to evaluate the clinical efficacy of repeated doses of
Leucocyte-poor Platelet-rich Plasma combined with Hyaluronic Acid and single dose of
Adipose Derived Mesenchymal Stem Cells injections. It was hypothesised that Adipose
Derived Mesenchymal Stem Cells could be superior to Leucocyte-poor Platelet-rich
Plasma + Hyaluronic Acid for the treatment of early knee Osteoarthritis at 12 months
follow-up.
Methods
Eighty knees in fifty patients (mean age: 61.3 years, range 40-80) with early knee
osteoarthritis were allocated into two groups from November 2016 to December 2017.
The group 1 composed of 40 knees were treated with three intra-articular injections (1
month apart) using autologous Leucocyte-poor Platelet Rich Plasma combined with
Hyaluronic Acid and the group 2 composed of 40 knees were treated with a single
dose of Adipose-derived Mesenchymal Stem Cell injection by supra-patellar approach.
Outcomes were measured by PROMs Tegner, Marx, VAS, IKDC and KOOS.
Results
All patients in both groups lead to clinical and functional improvement at 6 and 12
months. However, there is statistical significance evidence in favor of ADMSCs
(Lipogems) only for the case of Tegner and KOOS Symptoms at 6 months and for
Tegner at 12 months of follow-up.
Conclusion
This study shows both groups lead to clinical and functional improvement at 6 and 12
months. ADMSCs (Lipogems) showed better clinical results in Tegner and KOOS
Symptoms at 6 months and for Tegner at 12 months of follow-up. This finding will aid
clinicians to analyse the cost versus benefit ratio and help them to formulate an
algorithm when treating patients with early osteoarthritis.